Skip to main content
. 2014 May 27;66(6):1492–1503. doi: 10.1002/art.38392

Figure 6.

Figure 6

Recombinant IL‐22 (rIL‐22) modulates synovial fibroblast responses to IL‐17. A, Mice with CIA were injected twice weekly with rIL‐22 (0.25 μg/dose) in the right footpad or PBS (50 μl) in the left footpad (injection controls). Mice receiving no additional treatment were used as disease controls. IL‐22 injections were begun at the initiation phase of CIA (day 7 [early]) (n = 8) or around the time of onset of joint pathology (day 19 [late]) (n = 7). Values are the mean ± SEM (calculated using the mean clinical score of the 2 paws undergoing the same treatment in each individual mouse). B and C, Paws from individual mice with CIA receiving the indicated treatments, naive mice, and disease control mice with CIA were pooled to generate synovial fibroblast explant cultures representing the various treatment groups. Release of IL‐6 after 24 hours of treatment with medium alone (C) or with IL‐17 (B) was evaluated by enzyme‐linked immunosorbent assay. Values are the mean ± SEM (calculated using the mean of triplicate determinations of IL‐6 values from 3 independent cultures of cells from each treatment group). ∗ = P < 0.05; ∗∗ = P < 0.01; ∗∗∗ = P < 0.001 (P value shown for day 25 in the middle panel of A is versus untreated mice with CIA). See Figure 1 for other definitions.